昊海生科：2025年前三季度净利润约3.05亿元

Company Performance - Haohai Biological Technology reported Q3 performance with revenue of approximately 1.899 billion yuan, a year-on-year decrease of 8.47% [1] - The net profit attributable to shareholders was about 305 million yuan, down 10.63% year-on-year [1] - Basic earnings per share were 1.31 yuan, reflecting a decrease of 10.27% compared to the previous year [1] Market Context - As of the report, Haohai Biological Technology has a market capitalization of 11.7 billion yuan [2] - The Chinese innovative drug sector has seen significant overseas licensing deals totaling 80 billion US dollars this year [2] - Despite the hot secondary market for biopharmaceuticals, the primary market is experiencing a cooling in fundraising [2]